News Search Results
Jul 14, 2026, 08:37 ET Researchers from Incheon National University Develop a New Approach to Unlock Hidden Genetic Potential in Microbes
Trends in Biotechnology on March 1, 2026.To demonstrate the capabilities of the platform, the researchers selected naringenin, a plant-derived compound that
More news about: Incheon National University
Jul 14, 2026, 08:36 ET Skyhawk Therapeutics Announces Expansion of its Global Pivotal FALCON-HD Clinical Trial for SKY-0515 in Huntington's Disease to the United States, Canada and the United Kingdom
Skyhawk Therapeutics, Inc., a clinical-stage biotechnology company developing novel small molecule therapies designed to modulate RNA targets, announces it has received additional regulatory approvals to
More news about: Skyhawk Therapeutics
Jul 14, 2026, 08:33 ET Anixa Biosciences Expands Global Patent Portfolio with Australian Patent Acceptance for Breast Cancer Vaccine Technology
Calif., July 14, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that IP Australia has issued a Notice of Acceptance for a new patent
More news about: Anixa Biosciences, Inc.
Jul 14, 2026, 08:17 ET Skyhawk Therapeutics Announces Expansion of its Global Pivotal FALCON-HD Clinical Trial for SKY-0515 in Huntington's Disease to the United States, Canada and the United Kingdom
Skyhawk Therapeutics, Inc., a clinical-stage biotechnology company developing novel small molecule therapies designed to modulate RNA targets, announces it has received additional regulatory approvals to
More news about: Skyhawk Therapeutics
Jul 14, 2026, 08:00 ET Mighty Therapeutics Secures Up to $150 Million to Progress Commercial and Clinical Development of New Class of Mitochondrial Targeted Medicines
Mighty Therapeutics Holdings Inc. (the "Company" or "Mighty"), a commercial-stage biotechnology company pioneering a new class of medicines that directly target mitochondrial dysfunction in rare and age-related diseases, today announced the
More news about: Mighty Therapeutics
Jul 14, 2026, 07:45 ET Valion Bio Advances Integrated Biodefense and Immunology Platform Through Continued Government Engagement, Domestic Manufacturing and Oncology Expansion
These developments reflect the Company's evolution from a single product candidate into an integrated biotechnology platform. Taken together, these initiatives have significantly strengthened the Company's ability to pursue multiple avenues of near-, mid- and
More news about: Valion Bio, Inc.
Jul 14, 2026, 07:30 ET Illuminare Biotechnologies Appoints Veteran Biopharmaceutical Leader as New CEO
Directors has appointed Brian Longstreet as Chief Executive Officer, effective June 1, 2026. Brian brings 30 years of extensive pharmaceutical, biotechnology, and medical technology experience, including product clinical development and global commercialization. He built his career foundation in the large
More news about: Illuminare Biotechnologies
Jul 13, 2026, 17:36 ET FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer's Disease
LinkedIn.About Biogen Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patient's lives and to create value for shareholders and our communities.
More news about: Eisai Inc.
Jul 13, 2026, 16:01 ET Q32 Bio Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
WALTHAM, Mass., July 13, 2026 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB), ("Q32 Bio") a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata ("AA") and other autoimmune and inflammatory diseases, today announced that
More news about: Q32 Bio
Jul 13, 2026, 12:00 ET Pierre Guérin is building a new manufacturing facility in North Carolina
itself as a key player of equipment design, manufacturing, installation, and maintenance services for process industries such as pharmaceuticals and biotechnology. Its mission is to support its clients in high-value-added process industries in achieving operational excellence and sustainable performance.
More news about: Equans
Jul 13, 2026, 12:00 ET Converging at BIO, ACROBiosystems Connects Emerging Innovation Assets with Global Strategic Opportunities
across multiple therapeutic areas.About ACROBiosystems Group:ACROBiosystems Group, founded in 2010 and listed in 2021, is a biotechnology company aimed at being a cornerstone of the global biopharmaceutical and healthcare industries by providing innovative products and business models.
More news about: ACROBiosystems
Jul 13, 2026, 10:31 ET Metastatic Castration-resistant Prostate Cancer Market Poised for Strong Growth by 2036, Due to the Launch of Drug Classes Such as Anti-B7-H3 ADC, PROTAC Protein Degrader, NTD AR Inhibitor, Radionuclide Therapy, and Several Others | DelveInsight
2026, Bayer reported that the Phase II ARACOG (AFT-47) head-to-head study achieved its primary endpoint. In February 2026, Vir Biotechnology, Inc. presented updated Phase 1 trial data for VIR-5500, a PSMA-targeting PRO-XTEN® dual-masked T-cell engager, in heavily pretreated patients
More news about: DelveInsight Business Research, LLP
Jul 13, 2026, 10:00 ET Worcester Polytechnic Institute Goes Live with FOLIO in Partnership with EBSCO Information Services
George C. Gordon Library supports thousands of students and faculty across disciplines ranging from robotics and biotechnology to data science and the humanities. To advance this mission, WPI is adopting
More news about: EBSCO Information Services
Jul 13, 2026, 09:05 ET U.S. Food and Drug Administration Accepts BioMarin's Supplemental New Drug Application for Full Approval of VOXZOGO® (vosoritide) for Children With Achondroplasia
Patient Information. About BioMarinBioMarin is a leading, global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. Founded in 1997, the San Rafael, California-based
More news about: BioMarin Pharmaceutical Inc.
Jul 13, 2026, 08:00 ET Delonix Bioworks Announces First Participant Dosed in Phase 1 Clinical Trial of Next-Generation MenB OMV Vaccine DX-104 in China
SHANGHAI, July 13, 2026 /PRNewswire/ -- Delonix Bioworks, a clinical-stage biotechnology company pioneering genetically engineered bacterial vaccines, today announced that the first participant has been dosed in its Phase 1 clinical
More news about: Delonix Bioworks
Jul 13, 2026, 07:00 ET Armata Pharmaceuticals Receives Agreement from FDA on Initial Pediatric Study Plan for AP-SA02 for the Treatment of Complicated Staphylococcus aureus Bacteremia
July 13, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat
More news about: Armata Pharmaceuticals, Inc.
Jul 13, 2026, 06:59 ET Q32 Bio Announces Positive 36-Week Topline Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata
WALTHAM, Mass., July 13, 2026 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata ("AA") and other autoimmune and inflammatory diseases, today announced positive
More news about: Q32 Bio
Jul 13, 2026, 06:00 ET NeuroTherapia to Present Phase 2a Alzheimer's Disease Clinical Data at the AAIC 2026 Conference in London, UK
and deadly central nervous system (CNS) diseases patients and their families face today. NeuroTherapia, Inc. is a clinical-stage, privately held biotechnology company, spun out of the Cleveland Clinic, developing oral, small-molecule drugs to address neuroinflammatory conditions of the CNS, including Alzheimer's
More news about: NeuroTherapia, Inc.
Jul 13, 2026, 04:56 ET Leads Biolabs Announces Multiple Studies Selected for ESMO 2026, Highlighting the Growing Global Competitiveness of Its Core Pipeline
the treatment of RRMM.About Leads BiolabsFounded in 2012, Leads Biolabs is a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of innovative therapies to address underserved medical needs in oncology,
More news about: Leads Biolabs
Jul 13, 2026, 04:53 ET Boostimmune Secures Japanese Patent for Sequence-Independent TCTP Antibody Technology Targeting MDSC Accumulation
accelerate the development of BIO101 while actively pursuing strategic collaborations with global pharmaceutical and biotechnology companies."Boostimmune is an oncology-focused biotechnology company co-founded in 2021 by Gwanghee Lee and Professor Tadatsugu Taniguchi. The company is developing multiple
More news about: Boostimmune
Jul 12, 2026, 20:30 ET Deepening Collaboration in AI-Powered R&D Acceleration: Insilico Medicine and CMS announce additional collaborations in CNS diseases
SHANGHAI, July 12, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", 03696.HK), a clinical-stage biotechnology company driven by generative artificial intelligence (AI), and China Medical System Holdings Limited ("CMS", 867.HK/8A8.SG),
More news about: Insilico Medicine
Jul 12, 2026, 12:00 ET A New Approach to Treating Brain Cancer: HDT Bio Launches Canadian Clinical Program at McGill University
Canada, the U.S. Food and Drug Administration, or any other regulatory authority.About HDT Bio Corp. HDT Bio Corp. is a clinical-stage biotechnology company developing next-generation RNA and immune-activation technologies for oncology and infectious disease. The company's platforms are designed
More news about: HDT Bio Corp.
Jul 12, 2026, 11:15 ET LEQEMBI® Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer's Disease Presented at the Alzheimer's Association International Conference® (AAIC®) 2026
LinkedIn.About Biogen Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patient's lives and to create value for shareholders and our communities.
More news about: Eisai Inc.
Jul 10, 2026, 16:05 ET Q32 Bio to Report 36-Week Topline Results from Part B of SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata on July 13, 2026
WALTHAM, Mass., July 10, 2026 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata ("AA") and other autoimmune and inflammatory diseases, today announced it
More news about: Q32 Bio
Jul 10, 2026, 16:05 ET Virax Biolabs Group Limited Announces Closing of Exercise of Preferred Investment Options for $3.3 Million Gross Proceeds
securities laws of any such state or other jurisdiction.About Virax Biolabs Group LimitedVirax Biolabs Group Limited is a biotechnology company focused on immune response detection and T cell immune profiling. The Company is developing in vitro diagnostic technologies for viral and
More news about: Virax BioLabs Group Limited